Editas Medicine (EDIT) Total Non-Current Liabilities (2015 - 2025)

Editas Medicine (EDIT) has reported Total Non-Current Liabilities for 10 consecutive years, with $156.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 23.41% year-over-year to $156.4 million; the TTM figure through Dec 2025 stood at $156.4 million (down 23.41% YoY), while the FY2025 annual figure was $156.4 million, down 23.41% from the prior year.
• Total Non-Current Liabilities eased to $156.4 million in Q4 2025 per EDIT's latest filing, from $183.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $204.2 million in Q4 2024 and bottomed at $142.5 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $166.8 million across 4 years, with a median of $155.0 million in 2022.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 37.76% — and 2025, when it declined 23.41%.
• Editas Medicine's Total Non-Current Liabilities stood at $153.6 million in 2022, then retreated by 3.5% to $148.3 million in 2023, then soared by 37.76% to $204.2 million in 2024, then dropped by 23.41% to $156.4 million in 2025.
• Business Quant data shows EDIT's Total Non-Current Liabilities at $156.4 million in Q4 2025, $183.6 million in Q3 2025, and $186.8 million in Q2 2025.